Since significantly reduced expression of FCGR2B may be seen in AA+ individuals years before the onset of T1D (Table 2), this gene could potentially serve as an early biomarker of disease progression, and be used to predict disease onset. This evidence concerns the gene FCGR2B and type 1 diabetes mellitus.